
Olaparib, manufactured by pharmaceutical company AstraZeneca, could benefit hundreds who suffer from breast cancer and prostate cancer.
Men with advanced prostate cancer and women with a form of early breast cancer called HER2-negative will be able to access olaparib through NHS England if they are at high risk of the disease returning.